Becton Dickinson and Co (BDX)

How it makes money

BD generates revenue through sales of medical devices, supplies and diagnostic products to hospitals, healthcare systems, healthcare professionals and patients. The company sells directly to healthcare institutions and through distribution networks that include acute care, non-acute care, laboratory and pharmaceutical wholesalers. Revenue is dependent on third-party payer reimbursement decisions; BD has no direct control over payer coverage and payment levels.

Revenue by segment

BD possesses a portfolio of intellectual property including patents, trade secrets and trademarks across multiple geographies, along with established global distribution infrastructure, manufacturing scale and regulatory expertise. However, the company discloses that no single patent, technology or intellectual property asset is material to the business, indicating the moat is based on portfolio breadth and operational scale rather than singular innovations. Significant competition from low-cost manufacturers and new entrants in diagnostics continues to pressure pricing.

BD's medical supplies and diagnostic products serve critical healthcare functions with relatively stable underlying demand driven by aging populations and chronic disease prevalence. However, demand is not fully defensive: healthcare provider purchasing patterns, hospital capital budgets and third-party payer reimbursement policies can fluctuate with economic conditions and policy changes. Procedural volumes may decline during economic downturns.

Key risks

• Regulatory Compliance and Product Recalls — BD operates under an FDA Consent Decree governing infusion pumps with ongoing compliance obligations. The company received an FDA Warning Letter in November 2024 regarding BD Pyxis dispensing systems quality management. Regulatory authorities have the power to mandate recalls, seizures and civil or criminal sanctions, which could result in significant business interruption and costs.
• Supply Chain Dependence — BD depends on sole-sourced raw materials and components for certain products. Qualification of alternative suppliers can require 3-18 months of testing, or 1-3 years when clinical trials are needed. Supply disruptions, cost increases or termination of supplier relationships could materially impact manufacturing capability and profitability.
• Competitive Pricing Pressure — Entry of low-cost manufacturers into BD's markets has created increased pricing pressures. New competitors are emerging in molecular diagnostics, point-of-care testing and safety-engineered devices. Established companies are also diversifying into medical technology, increasing competitive intensity and potentially compressing margins.
• Reimbursement and Payer Risk — BD has no direct control over third-party payer decisions regarding coverage and payment levels. Healthcare systems are consolidating, creating concentrated markets among payers. Government programs are transitioning toward value-based payment models that emphasize quality and cost control. Unfavorable payer decisions could reduce demand and pricing power for BD's products.
• Foreign Exchange and Geographic Risk — BD operates globally with significant international revenues exposed to currency fluctuations. The company notes that foreign economic conditions and exchange rate fluctuations have caused profitability from foreign revenues to fluctuate more than profitability from domestic revenues. Operations in certain international jurisdictions carry greater political and economic risk.
• Integration and Separation Execution Risk — BD is integrating the Edwards Lifesciences Critical Care Product Group acquisition ($3.9 billion) while simultaneously managing the proposed separation of its Biosciences and Diagnostic Solutions segments through combination with Waters Corporation. Complex integrations and divestitures carry execution risk, regulatory approval uncertainty and potential impacts on near-term financial performance.